Inhibitory effect of ouabain on epinephrine-induced stimulation of adrenal corticosterone secretion in rats.
Chronic administration of ouabain (3 mg/Kg body weight, subcutaneously, once daily for consecutive 15 days) definitely inhibited epinephrine-induced increase of adrenal corticosterone secretion. The inhibition rate increased along with frequency of ouabain administration. Increase in adrenal corticosterone synthesis and secretion by ACTH (20-50 mU/rat) administration was partially suppressed by pretreatment with chronic ouabain administration. A slight but significant increase of adrenal corticosterone secretion caused by epinephrine administration in hypophysectomized rats was also inhibited by pretreatment with ouabain administration. Chronic administration of neither phentolamine (1 mg/rat, intraperitoneally, once daily for consecutive 15 days) nor propranolol (3 mg/Kg body weight, subcutaneously, once daily for consecutive 15 days) caused significant changes in adrenal corticosterone secretion in response to ACTH as well as to epinephrine. Chronic administration of ouabain in rats causes not only elevated secretion of ACTH from anterior pituitary but also functional change in adrenals leading to suppression of corticosterone secretion in response to ACTH or epinephrine administration.
D000302:Adrenal Cortex / Q000378:metabolism*; D000311:Adrenal Glands / Q000378:metabolism*; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000818:Animals; D003345:Corticosterone / Q000378:metabolism*; D004837:Epinephrine / Q000494:pharmacology*; D007016:Hypophysectomy; D008297:Male; D010042:Ouabain / Q000494:pharmacology*; D010646:Phentolamine / Q000494:pharmacology; D010902:Pituitary Gland / Q000502:physiology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D013268:Stimulation, Chemical
D010042:Ouabain; D000324:Adrenocorticotropic Hormone; D011433:Propranolol; D003345:Corticosterone; D004837:Epinephrine; D010646:Phentolamine